Send to a Friend Share

Cleveland BioLabs, Inc. (CBLI) Receives an Increase in DoD Protectan CBLB502 Contract

October 6, 2009 9:31 AM EDT
CBLI Hot Sheet
Overall Analyst Rating:
    BUY (Up Up)
Cleveland BioLabs, Inc. (Nasdaq: CBLI) announced today that the Chemical Biological Medical Systems Medical Identification and Treatment Systems Joint Program Executive Office (CBMS-MITS JPEO) of The Department of Defense (DoD) incresed the ongoing contract for the developmental studies related to Protectan CBLB502. The contract, awarded in April 2008, will increase from $8.86 million to $9.59 million.

You May Also Be Interested In


Related Categories

Corporate News

Add Your Comment





Follow StreetInsider.com On Twitter